In solution-phase assembly of therapeutic peptide APIs, L-serine methyl ester hydrochloride is introduced as a C-terminal carboxyl-protected building block after neutralization of the hydrochloride with a tertiary amine. The salt is suspended in 4:1 dichloromethane/DMF at 0–5°C, and 1.0–1.05 molar equivalents of N-methylmorpholine or diisopropylethylamine are added to liberate the free amino ester before coupling is initiated. Coupling with an N-acylated amino acid or peptide fragment is performed with 1.0–1.1 molar equivalents of EDC·HCl/HOBt or TBTU/HOBt relative to the acid component; the amino ester component is charged at 1.0–1.1 molar equivalents to compensate for residual water and amine titration errors. The reaction is monitored by RP-HPLC according to USP 621 until the limiting reagent is consumed; the organic phase is then washed sequentially with 5% sodium bicarbonate, 0.1 N hydrochloric acid, and brine, keeping aqueous phase pH between 6.5 and 7.5 to limit methyl ester hydrolysis. Solvent is evaporated on a diaphragm pump at <10 mbar and the residue is crystallized from methyl tert-butyl ether/heptane or purified by preparative C18 HPLC with 0.1% trifluoroacetic acid in water/acetonitrile. ICH Q7 Sections 7.1, 7.3, and 8.1 govern batch release, while ICH Q11 Section 3.2 applies to starting material specification and process control. Residual solvent limits follow ICH Q3C and USP 467; process-scale equipment is typically a 50–1000 L glass-lined or Hastelloy reactor with PTFE-sheathed thermocouples and a thermostatted jacket capable of maintaining ±1°C. The major process conflict is methyl ester hydrolysis, which becomes measurable by LC-MS when aqueous quench pH exceeds 8.5 for more than 15 min; diketopiperazine by-products also increase above 20°C when free amine and methyl ester coexist in the coupling medium. End products are therapeutic peptide APIs of 3–15 amino acid residues containing a C-terminal L-serine methyl ester, which are then advanced through salt exchange, lyophilization, and final sterile filtration as required by the target drug product.

Does residual methyl ester cleavage destabilize cosmetic peptide actives during final saponification?

Cosmetic peptide active manufacture with L-serine methyl ester hydrochloride requires retention of the methyl ester until final chain assembly is complete; the carboxyl terminus is then converted to the free acid by low-temperature alkaline hydrolysis. For short synthetic peptides intended for topical formulations, L-serine methyl ester hydrochloride is coupled at the C-terminal position with 0.95–1.05 molar equivalents relative to the N-acylated peptide acid, using a water-soluble carbodiimide and N-hydroxysuccinimide in aqueous acetonitrile at 0–5°C; after coupling, unconsumed amino ester is removed by ion-exchange chromatography or preparative C18 HPLC. Saponification of the C-terminal methyl ester requires 1.05–1.15 molar equivalents of sodium hydroxide in 1:1 dioxane/water at 0–5°C for 30–45 min; the pH is never allowed to exceed 12 because β-elimination of the serine side-chain hydroxyl to dehydroalanine becomes detectable above that threshold, and the resulting impurity is observable by HPLC at 214 nm with an acceptance limit of ≤0.15%. The production environment is bound by ISO 22716:2007 clauses 5.9.1 and 8.1 for cosmetic GMP, and finished peptide actives must satisfy the safety assessment requirements of EC 1223/2009 Annex II and Annex III entries applicable to peptide ingredients. If the peptide will be used in preservative-free or anhydrous formulations, residual water is controlled by lyophilization to <2.0% by Karl Fischer titration, and residual dioxane is limited by USP 467. Published data for the exact dehydroalanine formation threshold under this solvent mixture is limited; process transfer batches therefore require forced degradation studies under pH 12.5, 25°C, and 60 min to establish product-specific acceptance criteria. Terminal cosmetic product forms include anti-aging serums, peptide-loaded hydrogel patches, hair repair concentrates, and eye contour emulsions in which the synthetic peptide active is present at 50–500 ppm by mass.

Acyl serinate surfactant production via pH-controlled N-acylation of L-serine methyl ester hydrochloride

Acylation of L-serine methyl ester hydrochloride with fatty acid chlorides proceeds under Schotten-Baumann conditions in a jacketed stainless-steel reactor equipped with pH-stat control and external cooling. The amino ester hydrochloride is dissolved in aqueous acetone or aqueous tetrahydrofuran, and a 1.0:1.05 molar ratio of fatty acid chloride to amino ester is used; lauroyl chloride or cocoyl chloride is added over 2–4 h while maintaining 0–10°C and pH 10.5–11.5 with 30% sodium hydroxide. After acylation, the methyl ester is saponified by increasing the reactor temperature to 40–50°C and adding 2.5–3.0 molar equivalents of sodium hydroxide; the endpoint is confirmed when residual methyl ester by GC is <0.3%, and methanol released during saponification is removed by vacuum stripping at 80–120 mbar. The resulting acyl serinate is acidified with hydrochloric acid, filtered, washed with water, and neutralized to pH 6.0–6.8 before preservation. Regulatory compliance is anchored to REACH Annex VII Section 7.1 for substance registration, EC 648/2004 Annex II for ultimate aerobic biodegradation of surfactants, and OECD 301B for ready biodegradability with a 28 d mineralization threshold of 60% CO₂ evolution; natural origin index is determined by ISO 16128. Residual methanol and acetone are controlled by USP 467 or an equivalent gas chromatographic method. End products include sulfate-free liquid cleansers, baby wash, facial cleansing gels, and syndet bars where sodium lauroyl L-serinate or sodium cocoyl L-serinate functions as the primary or secondary surfactant.

Sequential N-protection of L-serine methyl ester hydrochloride with Boc anhydride in tetrahydrofuran gives methyl (S)-N-(tert-butoxycarbonyl)serinate, which is transformed into the corresponding oxazolidine acetonide with 2,2-dimethoxypropane. The N-protection step charges 1.05–1.2 molar equivalents of Boc anhydride and 1.5–2.0 molar equivalents of sodium bicarbonate relative to the amino ester, and the reaction is held at 0–5°C until ninhydrin testing confirms complete amine consumption. Acetonide formation uses 2–3 molar equivalents of 2,2-dimethoxypropane and 0.05–0.1 molar equivalents of p-toluenesulfonic acid in acetone, with water removed azeotropically; excess reagent is distilled under reduced pressure. The methyl ester is then reduced to the aldehyde with 2.2–2.5 molar equivalents of diisobutylaluminum hydride in toluene at -78°C; the hydride solution is added dropwise, and the reaction temperature must not rise above -65°C during addition because over-reduction to the corresponding alcohol becomes the dominant pathway. Quenching uses aqueous Rochelle salt, and the crude Garner’s aldehyde is purified by vacuum distillation at 80–90°C and 1–3 mbar or by filtration through triethylamine-deactivated silica gel; aldehyde purity is assayed by chiral GC or HPLC according to USP 621. ICH Q7 Section 8.1 and ICH Q11 Section 5.2 apply when this compound is a registered starting material for pharmaceutical synthesis; the specification includes chiral purity ≥98.5%, water content <0.1%, and residual tin or aluminum by inductively coupled plasma mass spectrometry depending on the hydride source. The acetonide ring is sensitive to aqueous acid, and exposure to pH below 4 at 25°C leads to ring opening; therefore all work-up solutions are buffered at pH 7.0–7.5. Downstream end products include sphingosine analogs, chiral amino alcohols, β-amino acid intermediates, and oxazolidinone-derived chiral auxiliaries used in asymmetric pharmaceutical syntheses.

When Fmoc protection of L-serine methyl ester hydrochloride is scaled for automated solid-phase peptide synthesis

Automated solid-phase peptide synthesis campaigns require Fmoc-protected amino acid derivatives with controlled residual water and high chromatographic purity; L-serine methyl ester hydrochloride enters this route as the N-Fmoc-protected methyl ester. The hydrochloride is dissolved in 1:1 dioxane/water, and 1.1–1.2 molar equivalents of Fmoc chloride are added at 0–5°C while pH is maintained at 8.5–9.0 with 10% sodium carbonate. Completion is confirmed by thin-layer chromatography or LC-MS; the organic layer is extracted with ethyl acetate, washed with water and saturated brine, dried over magnesium sulfate, and evaporated below 30°C to avoid premature Fmoc cleavage. The product is crystallized from ethyl acetate/heptane, and release testing follows USP 621 for chromatographic purity, USP 467 for residual solvents, and Karl Fischer titration for water; the residual Fmoc-chloride content is controlled at <0.1% because it generates Fmoc-dipeptide and deletion peptides during automated synthesis. For conversion to Fmoc-L-serine-OH, the methyl ester is hydrolyzed with 1.05–1.1 molar equivalents of lithium hydroxide in 3:1 tetrahydrofuran/water at 0°C for 45–60 min; the pH is kept below 8.0 during aqueous work-up to avoid Fmoc deprotection. The resulting protected amino acid is used in automated peptide synthesizers with resin loading 0.6–0.8 mmol/g, Fmoc deprotection in 20% piperidine/DMF, and coupling with HCTU/DIPEA; end products include SPPS-grade building blocks, custom research-grade peptides, and longer peptide intermediates for drug discovery. ICH Q3C and USP 467 limits apply to residual dioxane and ethyl acetate, and the relevant quality management system is ISO 9001:2015; for pharmaceutical intermediates, ICH Q7 Section 7.1 governs material handling.